Study to Evaluate Romosozumab in Children & Adolescents With Osteogenesis

See also
Status	Clinical Trial	Phase
Completed	`NCT03557567` - NGS Strategy Effectiveness in Molecular Diagnosis
Not yet recruiting	`NCT05559801` - Mesenchymal Cell Therapy in Osteogenesis Imperfecta (OI)	Phase 1/Phase 2
Active, not recruiting	`NCT02531087` - Urinary Biomarkers of OI Pathobiology
Completed	`NCT01713231` - Effect of High-Dose Vitamin D on Bone Density in Osteogenesis Imperfecta	Phase 4
Completed	`NCT00655681` - Prevention of Post Operative Bone Loss in Children	N/A
Recruiting	`NCT06065111` - Study of Osteogenesis Imperfecta Tendon
Withdrawn	`NCT03216486` - An Exploratory Study of BPS804 Treatment in Adult Patients With Type I, III or IV Osteogenesis Imperfecta	Phase 2
Recruiting	`NCT06086613` - A First-in-Human Study Evaluating AGA2115 in Adult Healthy Volunteers	Phase 1
Completed	`NCT04009733` - Epigenetic Regulation of Osteogenesis Imperfecta Severity : miROI Study	N/A
Completed	`NCT04231916` - High Resolution Thermal Imaging to Identify Vertebral Fractures in Children and Young People With Osteogenesis Imperfecta	N/A
Active, not recruiting	`NCT02814591` - Development of a Non-invasive Assessment of Human Bone Quality Using Spatially Offset Raman Spectroscopy
Completed	`NCT00982124` - An Efficacy and Safety Trial of Intravenous Zoledronic Acid in Infants Less Than One Year of Age, With Severe Osteogenesis Imperfecta	Phase 3
Completed	`NCT00001305` - Growth Hormone Therapy in Osteogenesis Imperfecta	Phase 3
Completed	`NCT04119388` - Evaluation of the Benefits of Adaptive Physical Activity in Children and Adolescents With Osteogenesis Imperfecta	N/A
Terminated	`NCT01679080` - The Effect of Treatment With Teriparatide and Zoledronic Acid in Patients With Osteogenesis Imperfecta	Phase 2
Completed	`NCT00106028` - Safety and Efficacy of Risedronate in the Treatment of Osteogenesis Imperfecta in Children	Phase 3
Recruiting	`NCT04152551` - Effects of Bisphosphonates on OI-Related Hearing Loss	Phase 4
Completed	`NCT00705120` - Treatment of Severe Osteogenesis Imperfecta by Allogeneic Bone Marrow Transplantation	Phase 1
Recruiting	`NCT04169568` - Osteogenesis Imperfecta Blood Pressure Study
Completed	`NCT03064074` - Safety of Fresolimumab in the Treatment of Osteogenesis Imperfecta	Phase 1

NCT number	NCT04545554
Study type	Interventional
Source	Amgen
Contact
Status	Completed
Phase	Phase 1
Start date	January 21, 2021
Completion date	March 30, 2023

Study to Evaluate Romosozumab in Children and Adolescents With Osteogenesis Imperfecta

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms